MedTrace Logo

A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects

NCT04839926 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-04-09

No results posted yet for this study

Summary

The primary objective of single ascending dose study is to evaluate the safety and tolerability of CY150112 after single oral administration of different doses in healthy Chinese subjects.

Conditions

Interventions

DRUG

0.5mg CY150112

single oral CY150112 while fasting on day 1.

DRUG

1.5mg CY150112

single oral CY150112 while fasting on day 1.

DRUG

4.5mg CY150112

single oral CY150112 while fasting on day 1.

DRUG

10mg CY150112

single oral CY150112 while fasting on day 1.

DRUG

18mg CY150112

single oral CY150112 while fasting on day 1.

DRUG

24mg CY150112

single oral CY150112 while fasting on day 1.

Sponsors & Collaborators

  • Jiangsu Nhwa Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hua Fang li, MD · Shanghai Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-02
Primary Completion
2021-08-01
Completion
2021-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04839926 on ClinicalTrials.gov